1. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Issue 10155 (13th October 2018) Authors: van Vollenhoven, Ronald F; Hahn, Bevra H; Tsokos, George C; Wagner, Carrie L; Lipsky, Peter; Touma, Zahi; Werth, Victoria P; Gordon, Robert M; Zhou, Bei; Hsu, Benjamin; Chevrier, Marc; Triebel, Manon; Jordan, Jarrat L; Rose, Shawn Journal: Lancet Issue: Volume 392:Issue 10155(2018) Page Start: 1330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗